Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fibrinolytic Agents | 6 | 2025 | 280 | 0.970 |
Why?
|
| Thrombolytic Therapy | 5 | 2025 | 149 | 0.850 |
Why?
|
| Tissue Plasminogen Activator | 5 | 2017 | 229 | 0.830 |
Why?
|
| Infarction, Middle Cerebral Artery | 2 | 2025 | 43 | 0.590 |
Why?
|
| Thrombectomy | 3 | 2025 | 73 | 0.590 |
Why?
|
| Intracranial Hemorrhages | 2 | 2025 | 89 | 0.510 |
Why?
|
| Stroke | 6 | 2020 | 1136 | 0.500 |
Why?
|
| Cerebral Infarction | 2 | 2014 | 49 | 0.410 |
Why?
|
| beta-Alanine | 1 | 2012 | 17 | 0.380 |
Why?
|
| Antithrombins | 1 | 2012 | 62 | 0.360 |
Why?
|
| Endovascular Procedures | 3 | 2025 | 349 | 0.350 |
Why?
|
| Benzimidazoles | 1 | 2012 | 181 | 0.340 |
Why?
|
| Viridans Streptococci | 1 | 2009 | 7 | 0.320 |
Why?
|
| Hypothermia, Induced | 1 | 2010 | 90 | 0.310 |
Why?
|
| Endocarditis, Bacterial | 1 | 2009 | 46 | 0.300 |
Why?
|
| Corynebacterium Infections | 1 | 2009 | 42 | 0.290 |
Why?
|
| Cerebral Hemorrhage | 3 | 2015 | 114 | 0.280 |
Why?
|
| Atrial Fibrillation | 1 | 2012 | 377 | 0.280 |
Why?
|
| Streptococcal Infections | 1 | 2009 | 148 | 0.270 |
Why?
|
| Specialization | 1 | 2008 | 128 | 0.270 |
Why?
|
| Disease Management | 1 | 2011 | 622 | 0.260 |
Why?
|
| Neurology | 1 | 2008 | 111 | 0.250 |
Why?
|
| Medicine | 1 | 2008 | 125 | 0.250 |
Why?
|
| Heart Arrest | 1 | 2010 | 383 | 0.250 |
Why?
|
| Critical Care | 2 | 2020 | 640 | 0.220 |
Why?
|
| Brain Ischemia | 2 | 2020 | 343 | 0.200 |
Why?
|
| Epidemiologists | 1 | 2022 | 5 | 0.190 |
Why?
|
| Sulfatases | 1 | 2021 | 5 | 0.180 |
Why?
|
| Acetylglucosaminidase | 1 | 2021 | 7 | 0.180 |
Why?
|
| Protein Sorting Signals | 1 | 2021 | 20 | 0.180 |
Why?
|
| Morals | 1 | 2022 | 75 | 0.170 |
Why?
|
| Peptide Fragments | 1 | 2025 | 693 | 0.170 |
Why?
|
| Cerebral Angiography | 2 | 2012 | 113 | 0.170 |
Why?
|
| Lysosomes | 1 | 2021 | 146 | 0.170 |
Why?
|
| Education, Professional | 1 | 2020 | 18 | 0.160 |
Why?
|
| Life Support Care | 1 | 2020 | 39 | 0.160 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2017 | 2698 | 0.150 |
Why?
|
| Central Nervous System Diseases | 1 | 2020 | 72 | 0.150 |
Why?
|
| Neuroprotective Agents | 1 | 2020 | 138 | 0.150 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 1352 | 0.140 |
Why?
|
| Treatment Outcome | 9 | 2025 | 10923 | 0.140 |
Why?
|
| Cerebral Intraventricular Hemorrhage | 1 | 2017 | 5 | 0.130 |
Why?
|
| Severity of Illness Index | 4 | 2025 | 2851 | 0.130 |
Why?
|
| Therapeutic Irrigation | 1 | 2017 | 79 | 0.130 |
Why?
|
| Sodium Chloride | 1 | 2017 | 138 | 0.120 |
Why?
|
| Drainage | 1 | 2017 | 173 | 0.120 |
Why?
|
| Hematoma, Subdural, Acute | 1 | 2015 | 3 | 0.120 |
Why?
|
| Aged, 80 and over | 8 | 2025 | 7677 | 0.120 |
Why?
|
| Perfusion Imaging | 2 | 2014 | 62 | 0.120 |
Why?
|
| Tertiary Care Centers | 1 | 2015 | 168 | 0.110 |
Why?
|
| Middle Aged | 12 | 2025 | 33604 | 0.110 |
Why?
|
| Peptides | 1 | 2020 | 976 | 0.110 |
Why?
|
| Patient Transfer | 1 | 2015 | 178 | 0.100 |
Why?
|
| Aged | 10 | 2025 | 24024 | 0.100 |
Why?
|
| Thrombin Time | 1 | 2012 | 14 | 0.100 |
Why?
|
| Dabigatran | 1 | 2012 | 23 | 0.090 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2012 | 45 | 0.090 |
Why?
|
| International Normalized Ratio | 1 | 2012 | 47 | 0.090 |
Why?
|
| Partial Thromboplastin Time | 1 | 2012 | 53 | 0.090 |
Why?
|
| Humans | 19 | 2025 | 138651 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1567 | 0.090 |
Why?
|
| Thiazolidinediones | 1 | 2012 | 138 | 0.090 |
Why?
|
| Brain Edema | 1 | 2011 | 64 | 0.090 |
Why?
|
| Double-Blind Method | 3 | 2025 | 1949 | 0.090 |
Why?
|
| Hematoma | 1 | 2011 | 54 | 0.080 |
Why?
|
| Stillbirth | 1 | 2010 | 73 | 0.080 |
Why?
|
| Fatal Outcome | 1 | 2010 | 309 | 0.080 |
Why?
|
| Heparin | 1 | 2011 | 258 | 0.080 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2009 | 68 | 0.070 |
Why?
|
| Male | 11 | 2025 | 68260 | 0.070 |
Why?
|
| Venous Thrombosis | 1 | 2011 | 190 | 0.070 |
Why?
|
| Infusions, Intravenous | 1 | 2009 | 411 | 0.070 |
Why?
|
| Critical Illness | 2 | 2020 | 831 | 0.070 |
Why?
|
| Female | 12 | 2025 | 73763 | 0.070 |
Why?
|
| Hyperglycemia | 1 | 2011 | 358 | 0.070 |
Why?
|
| Hypertensive Encephalopathy | 1 | 2006 | 1 | 0.070 |
Why?
|
| Intensive Care Units | 2 | 2015 | 853 | 0.070 |
Why?
|
| Choroid Diseases | 1 | 2006 | 11 | 0.070 |
Why?
|
| Venous Thromboembolism | 1 | 2011 | 324 | 0.060 |
Why?
|
| Health Services Needs and Demand | 1 | 2008 | 277 | 0.060 |
Why?
|
| Brain Stem | 1 | 2006 | 96 | 0.060 |
Why?
|
| Retinal Diseases | 1 | 2006 | 96 | 0.060 |
Why?
|
| Education, Medical | 1 | 2008 | 268 | 0.060 |
Why?
|
| Fellowships and Scholarships | 1 | 2008 | 310 | 0.050 |
Why?
|
| Societies, Medical | 1 | 2008 | 839 | 0.050 |
Why?
|
| Hypoglycemic Agents | 1 | 2012 | 1341 | 0.050 |
Why?
|
| Radiography | 2 | 2015 | 841 | 0.050 |
Why?
|
| Cricetulus | 1 | 2021 | 110 | 0.040 |
Why?
|
| CHO Cells | 1 | 2021 | 167 | 0.040 |
Why?
|
| Cricetinae | 1 | 2021 | 297 | 0.040 |
Why?
|
| Disks Large Homolog 4 Protein | 1 | 2020 | 19 | 0.040 |
Why?
|
| Certification | 1 | 2020 | 116 | 0.040 |
Why?
|
| Emergencies | 1 | 2020 | 178 | 0.040 |
Why?
|
| Adult | 5 | 2014 | 38201 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2014 | 2030 | 0.040 |
Why?
|
| Pregnancy | 1 | 2010 | 6829 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2025 | 7554 | 0.030 |
Why?
|
| Acute Disease | 1 | 2020 | 994 | 0.030 |
Why?
|
| Retrospective Studies | 4 | 2015 | 15909 | 0.030 |
Why?
|
| Glasgow Coma Scale | 1 | 2015 | 200 | 0.030 |
Why?
|
| Injections, Intra-Arterial | 1 | 2013 | 26 | 0.030 |
Why?
|
| Reperfusion | 1 | 2013 | 44 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 1229 | 0.030 |
Why?
|
| Stress, Psychological | 1 | 2022 | 1119 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2014 | 351 | 0.020 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2011 | 36 | 0.020 |
Why?
|
| Length of Stay | 1 | 2015 | 1238 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 5803 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 2049 | 0.020 |
Why?
|
| Amlodipine | 1 | 2006 | 10 | 0.020 |
Why?
|
| Metoprolol | 1 | 2006 | 25 | 0.020 |
Why?
|
| Valsartan | 1 | 2006 | 30 | 0.020 |
Why?
|
| Tetrazoles | 1 | 2006 | 44 | 0.020 |
Why?
|
| Valine | 1 | 2006 | 77 | 0.020 |
Why?
|
| Fluorescein Angiography | 1 | 2006 | 167 | 0.020 |
Why?
|
| Registries | 1 | 2014 | 2073 | 0.010 |
Why?
|
| Prognosis | 1 | 2013 | 3984 | 0.010 |
Why?
|
| Mice | 1 | 2021 | 17814 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2006 | 1032 | 0.010 |
Why?
|
| Adolescent | 2 | 2013 | 21564 | 0.010 |
Why?
|
| Antihypertensive Agents | 1 | 2006 | 505 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2006 | 1739 | 0.010 |
Why?
|
| Animals | 1 | 2021 | 37217 | 0.010 |
Why?
|
| Young Adult | 1 | 2012 | 13305 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2006 | 3637 | 0.010 |
Why?
|